At Wnt 2022 to Be Held in Japan in Nov.
JW Pharmaceutical announced on Oct. 31 that it will make a poster presentation on the results of a preclinical study on JW0061, a Wnt target hair loss treatment, at Wnt 2022, a conference to be held in Japan for five days from Nov. 15.
Wnt is an acronym in the field of genetics that stands for 'Wingless/Integrated.' The conference is a forum for world-renowned scholars and researchers in the field of Wnt signaling pathways to exchange the latest knowledge and research results.
At the conference, JW Pharmaceutical will unveil the newly identified mode of action (MoA) of JW0061 and the results of an efficacy evaluation of an animal model tested with clinical formulations for the first time. This will mark the first time for a Korean pharmaceutical/biotech company to present the research results of a new drug candidate at the international Wnt conference.
JW0061 is a first-in-class new drug candidate material that promotes the differentiation and proliferation of hair follicle stem cells and cells involved in hair growth by activating Wnt signaling pathways, which are reduced in the process of hair loss.